Klinge Biopharma

Klinge Biopharma's FYB203, licensed from German biosimilar developer Formycon AG, is currently being evaluated in a Phase 3 clinical trial (MAGELLAN-AMD), with topline results expected in the coming weeks. MAGELLAN-AMD is a randomized, double-blind, multicenter study designed to assess the efficacy and safety of FYB203 compared to the reference product Eylea® in patients with neovascular (wet) age-related macular degeneration (nAMD), including evaluations of safety, efficacy, and immunogenicity.